retatrutide glp 3 Subcutaneous Fat Loss Results: What Clinical Trials Reveal About Effectiveness and Safety GLP-3 (RT) Retatrutide | Advanced

Int J Mol Med 2017;39:102936.ArticlePubMed 57

At the same time, obesity can lead to irregular periods or heavier periods

Contraindications : GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

Tirzepatide produced greater A1c reductions in the SURPASS-2 head-to-head trial, making it the stronger option for glucose control

A Morgan Stanley AlphaWise survey of senior human resources executives showed that the percentage of employers covering GLP-1s for obesity rose from 44% in 2024 to 48% last year, with respondents projecting it to reach 65% by 2027

The clear lack of coverage underscores ongoing concerns about the long-term costs and sustainability of using high-priced GLP-1s for weight management without solid evidence of lasting results